Phathom Pharmaceuticals
PHAT
PHAT
133 hedge funds and large institutions have $1.31B invested in Phathom Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 29 funds opening new positions, 58 increasing their positions, 18 reducing their positions, and 10 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
133
Holders Change
+19
Holders Change %
+16.67%
% of All Funds
1.92%
Holding in Top 10
12
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+20%
% of All Funds
0.17%
New
29
Increased
58
Reduced
18
Closed
10
Calls
$4.5M
Puts
$1.05M
Net Calls
+$3.45M
Net Calls Change
-$1.13M
Top Buyers
| 1 |
1
Jennison Associates
New York
|
$106M |
| 2 |
WP
2
Woodline Partners
San Francisco,
California
|
$46.5M |
| 3 |
O
3
OrbiMed
New York
|
$26.2M |
| 4 |
4
Federated Hermes
Pittsburgh,
Pennsylvania
|
$25.4M |
| 5 |
5
Fidelity Investments
Boston,
Massachusetts
|
$23.6M |
Top Sellers
| 1 |
TPC
1
Takeda Pharmaceutical Company
Tokyo,
Japan
|
$0 |
| 2 |
6CM
2
683 Capital Management
New York
|
$18.3M |
| 3 |
3
Morgan Stanley
New York
|
$7.95M |
| 4 |
GTC
4
Ghost Tree Capital
New York
|
$6.78M |
| 5 |
5
Two Sigma Investments
New York
|
$2.78M |
